3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform
DE · EN Newsletter
Biotech & Pharma Symbolbild · KI-generiert
Biotech & Pharma ACRS

Aclaris Therapeutics, Inc.

ACRS NASDAQ Biotech & Pharma

Stock factsheet

TickerACRS
ExchangeNASDAQ
ISIN
WKN
SectorBiotech & Pharma
Size class Small Cap
Market capitalisation 726 Mio. USD As of 2026-08-03

Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.

Company profile

Aclaris Therapeutics is a pharmaceutical company focused on developing therapeutics for dermatological and immunological conditions. Its pipeline includes compounds for the treatment of alopecia and inflammatory diseases, among others.

Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.

Share price

Price data from TradingView, possibly delayed. Not investment advice.

Comparable companies

Companies in the Biotech & Pharma sector of a similar size.

CompanyTickerExchangeMarket cap
Aclaris Therapeutics, Inc.ACRS NASDAQ726 Mio. USD
Monopar Therapeutics Inc. MNPRNASDAQ 726 Mio. USD
Aura Biosciences, Inc. AURANASDAQ 725 Mio. USD
Candel Therapeutics, Inc. CADLNASDAQ 733 Mio. USD
Bright Minds Biosciences Inc. DRUGCSE 715 Mio. USD
Pharming Group N.V. ADS, each representing 10 ordinary shares PHARNASDAQ 712 Mio. USD
Faeth Therapeutics, Inc. FTHNASDAQ 702 Mio. USD

Investor Relations

Annual reports Not recorded yet
Investor presentation Not recorded yet
Analyst coverage Not recorded yet

We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.

Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.